Cell therapy company Chimeric Therapeutics (ASX:CHM) has announced that the Indian Patent Office has issued a patent covering certain applications of chimeric antigen receptor (CAR) technology using chlorotoxin (CLTX), including the company’s clinical-stage CAR-T asset CHM 1101 and preclinical stage CAR-NK asset CHM 1301.
The company said the India patent has been granted under patent number IN 424963, entitled ‘Chimeric antigen receptors containing a chlorotoxin domain’.
The Israel Patent Office also has issued an Official Notification Prior to Acceptance, a notice of allowance, for application IL 258670.
Chimeric holds the exclusive worldwide license to develop and commercialize IN 424963, IL 258670, and related patent applications filed in other global territories.
CEO and managing director Jennifer Chow said, “We are delighted to have patent protection granted for CLTX CAR therapies in India and shortly in Israel as we continue to expand the robust intellectual property portfolio underpinning our CLTX CAR pipeline assets.”
